• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    3/10/21 9:39:41 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TRVN alert in real time by email
    SC 13D/A 1 nea12-trevena_18475.htm NEW ENTERPRISE ASSOCIATES 12, LP (TREVENA) - SCHEDULE 13DA3E Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Trevena, Inc.

    (Name of Issuer)

    Common Stock, $.001 par value

    (Title of Class of Securities)

    89532E109

    (CUSIP Number)

    Louis S. Citron, Esq.

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600, Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    March 12, 2020

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 89532E109

    13D Page 2 of 8 Pages    

     

    Item 1.Security and Issuer.

     

    This Amendment No. 3 (“Amendment No. 3”) to Schedule 13D amends and supplements the statement on Schedule 13D originally filed on February 12, 2014, as amended on December 15, 2014 and December 17, 2015, relating to the common stock, $.001 par value (the “Common Stock”) of Trevena, Inc. (the “Issuer”) having its principal executive office at 955 Chesterbrook Blvd., Suite 110, Chesterbrook, PA.

     

    Certain terms used but not defined in this Amendment No. 3 have the meanings assigned thereto in the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto). Except as specifically provided herein, this Amendment No. 3 does not modify any of the information previously reported on the Schedule 13D (including Amendment No. 1 and Amendment No. 2 thereto).

     

     

    Item 2.Identity and Background.

     

    This statement is being filed by:

     

    (a) New Enterprise Associates 12, Limited Partnership (“NEA 12”, the “Fund” or the “Record Holder”);

     

    (b) NEA Partners 12, Limited Partnership (“NEA Partners 12” or the “GPLP”), which is the sole general partner of NEA 12; and NEA 12 GP, LLC (“NEA 12 LLC” and, together with the GPLP, the “Control Entities”), which is the sole general partner of NEA Partners 12; and

     

    (c) Forest Baskett (“Baskett”), Patrick J. Kerins (“Kerins”) and Scott D. Sandell (“Sandell”) (together, the “Managers”) and Michael James Barrett, Peter J. Barris and Krishna S. Kolluri. The Managers are the managers of NEA 12 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of the Record Holder, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Kerins is New Enterprise Associates, 5425 Wisconsin Avenue, Suite 800, Chevy Chase, MD 20815. The address of the principal business office of Baskett is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, California 94025.

     

    The principal business of the Fund is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 12 is to act as the sole general partner of NEA 12. The principal business of NEA 12 LLC is to act as the sole general partner of NEA Partners 12. The principal business of each of the Managers is to manage the Control Entities, the Fund and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    The Fund and the GPLP are limited partnerships organized under the laws of the State of Delaware. NEA 12 LLC is a limited liability company organized under the laws of the State of Delaware. Each of the Managers is a United States citizen.

     

     

    Item 4.Purpose of Transaction.

     

    Not applicable.

     

     

    Item 5.Interest in Securities of the Issuer.

     

    Each of the Reporting Persons has ceased to own beneficially five percent or more of the Issuer’s Common Stock.

     

     

    Item 7.Material to be Filed as Exhibits.

     

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

     

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

     

     

     

     

    CUSIP No. 89532E109

    13D Page 3 of 8 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 10th day of March, 2021.

     

     

    NEW ENTERPRISE ASSOCIATES 12, Limited Partnership

     

    By:              NEA PARTNERS 12, Limited Partnership

    General Partner

     

    By:      NEA 12 GP, LLC

    General Partner

     

    By:                          *                         

    Scott D. Sandell

    Manager

     

     

    NEA PARTNERS 12, Limited Partnership

     

    By:NEA 12 GP, LLC

    General Partner

     

    By:                           *                         

    Scott D. Sandell

    Manager

     

     

    NEA 12 GP, LLC

     

    By:                                   *                         

        Scott D. Sandell

        Manager

     

     

     

     
     

    CUSIP No. 89532E109

    13D Page 4 of 8 Pages    

     

     

     

     

     

     

                                *                            

    M. James Barrett

     

     

                                *                            

    Peter J. Barris

     

     

                                *                            

    Forest Baskett

     

     

                                *                            

    Patrick J. Kerins

     

     

                                *                            

    Krishna S. Kolluri

     

     

                                *                            

    Scott D. Sandell

     

     

     

     

     

     

              */s/ Sasha Keough             

    Sasha Keough

    As attorney-in-fact

     

     This Amendment No. 3 to Schedule 13D was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached as Exhibit 2.

     

     

     

     
     

    CUSIP No. 89532E109

    13D Page 5 of 8 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Trevena, Inc.

     

    EXECUTED this 10th day of March, 2021.

     

     

     

    NEW ENTERPRISE ASSOCIATES 12, Limited Partnership

     

    By:              NEA PARTNERS 12, Limited Partnership

    General Partner

     

    By:      NEA 12 GP, LLC

    General Partner

     

    By:                          *                         

    Scott D. Sandell

    Manager

     

     

    NEA PARTNERS 12, Limited Partnership

     

    By:NEA 12 GP, LLC

    General Partner

     

    By:                           *                         

    Scott D. Sandell

    Manager

     

     

    NEA 12 GP, LLC

     

    By:                                   *                         

        Scott D. Sandell

        Manager

     

     

     

     

     
     

    CUSIP No. 89532E109

    13D Page 6 of 8 Pages    

     

     

     

     

     

                                *                            

    Michael James Barrett

     

     

                                *                            

    Peter J. Barris

     

     

                                *                            

    Forest Baskett

     

     

                                *                            

    Patrick J. Kerins

     

     

                                *                            

    Krishna S. Kolluri

     

     

                                *                            

    Scott D. Sandell

     

     

     

     

     

              */s/ Sasha Keough             

    Sasha Keough

    As attorney-in-fact

     

    This Agreement relating to Schedule 13D was executed by Sasha Keough on behalf of the individuals listed above pursuant to a Power of Attorney a copy of which is attached hereto as Exhibit 2.

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 89532E109

    13D Page 7 of 8 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Louis S. Citron, Timothy Schaller, Sasha Keough and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 13th day of March, 2017.

     

     

    /s/ M. James Barrett            

    M. James Barrett

     

    /s/ Peter J. Barris                

    Peter J. Barris

     

    /s/ Forest Baskett                

    Forest Baskett

     

    /s/ Ali Behbahani                 

    Ali Behbahani

     

    /s/ Colin Bryant                   

    Colin Bryant

     

    /s/ Carmen Chang               

    Carmen Chang

     

    /s/ Anthony A. Florence, Jr.

    Anthony A. Florence, Jr.

     

    /s/ Carol G. Gallagher          

    Carol G. Gallagher

     

    /s/ Dayna Grayson               

    Dayna Grayson

     

    /s/ Patrick J. Kerins             

    Patrick J. Kerins

     

    /s/ P. Justin Klein                

    P. Justin Klein

     

     

     

     

     

    CUSIP No. 89532E109

    13D Page 8 of 8 Pages    

     

     

     

     

    /s/ Vanessa Larco               

    Vanessa Larco

     

    /s/ Joshua Makower             

    Joshua Makower

     

    /s/ Mohamad H. Makhzoumi

    Mohamad H. Makhzoumi

     

    /s/ Edward T. Mathers         

    Edward T. Mathers

     

    /s/ David M. Mott                

    David M. Mott

     

    /s/ Sara M. Nayeem            

    Sara M. Nayeem

     

    /s/ Jason R. Nunn                

    Jason R. Nunn

     

    /s/ Gregory Papadopoulos    

    Gregory Papadopoulos

     

    /s/ Chetan Puttagunta          

    Chetan Puttagunta

     

    /s/ Jon Sakoda                     

    Jon Sakoda

     

    /s/ Scott D. Sandell              

    Scott D. Sandell

     

    /s/ A. Brooke Seawell          

    A. Brooke Seawell

     

    /s/ Peter W. Sonsini             

    Peter W. Sonsini

     

    /s/ Melissa Taunton             

    Melissa Taunton

     

    /s/ Frank M. Torti                

    Frank M. Torti

     

    /s/ Ravi Viswanathan           

    Ravi Viswanathan

     

    /s/ Paul E. Walker               

    Paul E. Walker

     

    /s/ Rick Yang                      

    Rick Yang

     

      

    Get the next $TRVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRVN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TRVN
    SEC Filings

    See more
    • Trevena Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - TREVENA INC (0001429560) (Filer)

      5/15/25 8:09:22 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Trevena Inc.

      25-NSE - TREVENA INC (0001429560) (Subject)

      4/8/25 9:20:54 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Trevena Inc.

      NT 10-K - TREVENA INC (0001429560) (Filer)

      3/31/25 4:01:19 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors

      CHESTERBROOK, Pa. , July 20, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark Corrigan, M.D. has been appointed to the Company's Board of Directors, effective July 18 2023. "We are pleased to welcome Mark to Trevena's Board of Directors," said Carrie Bourdow, Trevena's President and CEO. "Mark has over 30 years of experience in the life sciences industry and broad neuroscience expertise. He will be an invaluable member of the Board and guide to the management team as we continue to execute on our corporate

      7/20/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Imvax Appoints John M. Limongelli as Chief Legal Officer

      Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company's Chief Legal Officer effective September 16, 2021. "John's breadth of experience in the biopharma industry, his deep technical acumen, and his expertise at helping build strong corporate practices will be of invaluable benefit to our leadership team," said John Furey, Chief Executive Officer. "As we work to expand our platform to address a variety of solid tumors, John's expertise will be an essential part of the development of these assets." Mr. Limongelli is an accomplished executive officer and lawyer with near

      9/16/21 8:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TRVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TRVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • New insider Sutton Katrine claimed ownership of 942 shares (SEC Form 3)

      3 - TREVENA INC (0001429560) (Issuer)

      12/6/24 4:39:03 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acting CMO Demitrack Mark covered exercise/tax liability with 885 shares, decreasing direct ownership by 7% to 11,363 units (SEC Form 4)

      4 - TREVENA INC (0001429560) (Issuer)

      10/10/24 5:08:47 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Acting COO and CFO Shin Barry covered exercise/tax liability with 806 shares, decreasing direct ownership by 7% to 11,543 units (SEC Form 4)

      4 - TREVENA INC (0001429560) (Issuer)

      10/10/24 5:07:55 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Trevena Inc.

      SC 13G/A - TREVENA INC (0001429560) (Subject)

      11/14/24 4:43:11 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Trevena Inc.

      SC 13G - TREVENA INC (0001429560) (Subject)

      9/19/24 4:09:55 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Trevena Inc. (Amendment)

      SC 13G/A - TREVENA INC (0001429560) (Subject)

      2/14/24 2:34:30 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Trevena

      Oppenheimer initiated coverage of Trevena with a rating of Market Perform

      3/15/21 7:02:03 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Trevana

      Oppenheimer initiated coverage of Trevana with a rating of Perform

      3/15/21 6:50:29 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Trevena Reports Third Quarter 2024 Results and Provides Business Update

      CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the third quarter ended September 30, 2024 and provided an overview of its recent operational updates. Third Quarter 2024 and Recent Corporate Updates $2 million Non-Dilutive Financing Tranche. In July 2024, the Company announced receipt of a non-dilutive, $2 million tranche in connection with an amendment (the "Amendment") to its existing ex-US royalty financing with R-Bridge Healthcare Fund ("R-Bridge"). The Compa

      11/7/24 7:01:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Receipt of Nasdaq Delisting Notification

      CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that on October 4, 2024 the Company received notice that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's common stock from The Nasdaq Stock Market LLC ("Nasdaq") due to the Company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard Rule"). As previously disclosed, the Panel had provided the Company until October 2, 2024, to regain comp

      10/4/24 4:05:00 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Reverse Stock Split

      CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to effect a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective at 12:01 a.m. ET on Tuesday, August 13, 2024. Trevena's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "TRVN" and will begin trading on a split-adjusted basis when the market opens on Tu

      8/8/24 4:05:00 PM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TRVN
    Financials

    Live finance-specific insights

    See more
    • Trevena Reports Third Quarter 2023 Results and Provides Business Update

      Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target engagement Company reported favorable safety and tolerability data from TRV045 POC studies Three abstracts for OLINVYK presented at American Society of Anesthesiologists (ASA) Conference $15 million tranche from ex-US royalty-based financing agreement received in September Company to host conference call today, November 14, 2023 at 8:00 a.m. ET CHESTERBROOK, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for pat

      11/14/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena to Release Third Quarter 2023 Financial Results on November 14, 2023

      CHESTERBROOK, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the third quarter ended September 30, 2023, prior to the market open on Tuesday, November 14, 2023. The Company will host a conference call and webcast with the investment community at 8:00 a.m. ET that same day, featuring remarks by Carrie Bourdow, President and Chief Executive Officer, Mark Demitrack, M.D., SVP and Chief Medical Officer, and Barry Shin, SVP and Chief Financial Office

      11/9/23 7:00:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Trevena Announces Receipt of $15 Million Non-Dilutive Tranche and Provides General Business Update

      $15 million tranche from ex-US royalty-based financing, triggered by first commercial sale of OLINVYK by Jiangsu Nhwa, Trevena's partner in China New OLINVYK respiratory data from VOLITION ~200 patient real-world outcomes study, using continuous respiratory monitoring, expected 3Q 2023 Three OLINVYK abstracts accepted for presentation at upcoming American Society of Anesthesiologists Meeting in 4Q 2023 Company to participate in upcoming HC Wainwright conference (September 11-13) Company to Hold Conference Call on Wednesday, September 6 at 8 a.m. Eastern Time to discuss TRV045 Proof-of-Concept Data CHESTERBROOK, Pa., Sept. 06, 2023 (GLOBE NEWSWI

      9/6/23 7:01:00 AM ET
      $TRVN
      Biotechnology: Pharmaceutical Preparations
      Health Care